c-LEcta GmbH

Since 2022 c-LEcta is part of the Kerry Group. Kerry is the world’s leading taste and nutrition partner for the food, beverage and pharmaceutical markets. The company employs 22,000 people across over 150 locations and uses its broad range of ingredient solutions to innovate with its customers and create great tasting products, with improved nutrition and functionality, while ensuring a better impact for the planet.
About c-LEcta GmbH: |
| Field of activity |
c-LEcta uses its proprietary technology platform ENESYZ® to develop customized enzymes and microbial production strains that meet the requirements of a wide variety of manufacturing processes in industry. |
| Main Shareholder |
Kerry Group |
| Partners | DSM, BASF, novozymes, Roche, symrise |
| Technology | New enzyme products are developed at c-LEcta using the company‘s unique technology platform, ENESYZ. The heart of the platform is a proprietary bioinformatics-based technology for efficient and targeted engineering of enzymes. |
| Products | Our enzyme products are used in the pharmaceutical industry as processing aids for the production of biopharmaceuticals and vaccines or as biocatalysts for the production of active chemical ingredients. For the food industry we provide enzymes for production of food ingredients and additives or as process aids in the production of foods and beverages. |
| Membership in Networks/Associations | amfep, Bio-Deutschland e.V., Vereinigung deutscher Biotechnologie-Unternehmen (VBU), Bio Saxony e.V. |
| Date of incorporation/number of employees | 2004/125 |
|
|
|
Contact: |
|
![]() |
|
| Thomas Pfaadt CFO |
|
| Address | Perlickstraße 5 04103 Leipzig |
| Telephone | +49 341 355 2140 |
| contact@c-lecta.com | |
| Web Address | www.c-lecta.com |
| Social Media | LinkedIn, X |
- „Wir investieren dort, wo es auf Technologie ankommt“
- Biotech und Life Sciences von Norden bis Süden
- Thomas Pfaadt als neuer Finanzvorstand der Vita 34 AG bestellt
- Richtfest für "BioSquare Leipzig"
- 8th ECP: Die hohe Bedeutung der Chemie wird bleiben
- Enzymhersteller c-LEcta von irischer Kerry Group übernommen
- c-LEcta knackt 10 Mio. Euro Umsatz mit deutlich gesteigertem EBITDA
- „Wir brauchen eine Matchingplattform in der Wachstumsphase“
- c-LEcta schließt Finanzierungsrunde ab

